Drug Detail
BI 1015550 is a selective, phosphodiesterase 4b inhibitor under development for patients with IPF
Study Purpose
To investigate the efficacy of BI 1015550 compared to placebo based on the change from baseline in Forced Vital Capacity (FVC).
To investigate safety and tolerability of BI 1015550 in the overall trial population.
